PQBP1 (polyglutamine tract-binding protein 1) is a causative gene for a relatively frequent X-linked syndromic and non-syndromic mental retardation (MR). To analyze behavioral abnormalities of these patients from molecular basis, we developed a knock-down (KD) mouse model. The KD mice possess a transgene expressing 498 bp double-strand RNA that is endogenously cleaved to siRNA suppressing PQBP1 efficiently. After confirming that PQBP1 is selectively suppressed to nearly 50% of the control mice, we performed behavioral analyses of PQBP1-KD mice. The KD mice possessed normal ability in ordinary memory tests including water-maze test, whereas they showed abnormal anxiety-related behavior in light/dark exploration test and open-field test and showed obvious declines of anxiety-related cognition in the repetitive elevated plus maze or novel object recognition test. Correspondingly, we found c-fos upregulation and histone H3 acetylation after behavior tests were declined in neurons of amygdala, prefrontal cortex and hippocampus. Furthermore, we found that 4-phenylbutyric acid, an HDAC inhibitor, efficiently improved expression of these genes and rescued the abnormal phenotypes in adult PQBP1-KD mice. These results suggested that PQBP1 dysfunction in regulating gene expression might underlie the abnormal behavior and cognition of PQBP1-KD mice and that the recovery of expression of such PQBP1 target genes might improve the symptoms in adult patients.
INTRODUCTION
Mental retardation (MR) is a highly frequent developmental disorder that affects nearly 1% of population in advanced countries. The causes are variable, although monogenic MR is a major group of MR in addition to multigenic and environmental factorinduced MR (1) . The dominance of male in MR is largely recognized (1) , and the relevance between X-linked MR genes and evolution of human intelligence is also suspected (2) . The frequency of MR genes in X chromosome is obviously higher than that in the other chromosomes, which might be used for evolutional selection of intelligence through males (2 -4) .
The most frequent X-linked MR is fragile-X syndrome that affects approximately one in 4000 males and one in 7000 females. The following group includes Rett syndrome that affects one in 6000 -10 000 males. Recently, mutations in PQBP1 (polyglutamine tract-binding protein 1) gene located at Xp11.23 were shown to be causative for syndromic and non-syndromic MR including Renpenning syndrome, Golabi -Ito-Hall and Sutherland -Haan syndromes (5 -9) . The frequency of all the PQBP1-linked MR patients seems to be rather high in western countries and might be equivalent to that of Rett syndrome (9) .
PQBP1 was isolated originally as a binding protein to the polyglutamine (polyQ) tract sequence (10) . PQBP1 is implicated in neurodegenerative pathologies because it interacts with mutant ataxin-1 (Atx1), the causative gene product of spinocerebellar ataxia type-1 (SCA1), and with huntingtin (Htt), the causative gene product of Huntington's disease (HD). PQBP1 interacts with phosphorylation sites of the C-terminal of RNA polymerase II (Pol II) (11) , the core molecule of transcription, and with several other proteins such as NpwBP/ SIPP/WBP11 (12, 13) and U5-15kD (14, 15) that are involved in RNA splicing. PQBP1 and these binding partners are identified in the splicing complex also by recent proteome analyses (16, 17) . Interaction between PQBP1 and mutant polyQ proteins might induce dysfunction of PQBP1 in transcription coupled with splicing (11, 18) . The similar dysfunction in transcription/splicing might occur in PQBP1-linked MR.
In this study, we generated a PQBP1-knock-down (KD) mouse model, to investigate the phenotype induced by PQBP1 deficiency and the molecular link between phenotype and PQBP1 mutations. We found impairment of anxiety-related cognition and memory, and detected abnormal expression of memory-related genes that could be induced by dysfunction of PQBP1-mediated transcription/splicing in this mouse model. Furthermore, we found that an histone deacetylase (HDAC) inhibitor, 4-phenylbutyric acid (PBA), that generally upregulates transcription and ameliorates neurodegeneration in animal models, rescued the abnormal behavior and memory of the PQBP1-KD mice.
RESULT

Generation of PQBP1-KD mouse
In this study, we employed the pDECAP system developed by Ishii and colleagues (19) to knock-down PQBP1. The pDECAP plasmid expresses double-strand RNA that is degraded by endogenous Dicer to siRNA suppressing the target mRNA (19) . We made three types of plasmids by subcloning three different partial PQBP1 cDNAs into pDECAP and compared their suppression efficiencies in P19 cells (Supplementary Material, Fig. S1 ). The most effective suppression was obtained by the fragment from 295 to 792 bp, thus we generated transgenic mice with pDECAP-PQBP1 (295 -792) ( Fig. 1A and B) .
We obtained two lines of mice with this construct. The expression levels of PQBP1 in the two lines were not statistically different (data not shown). Using two pups from line #1 and another two from line #2, we tested whether PQBP1 is selectively suppressed in pDECAP-PQBP1 transgenic mice in relevance to other control proteins with cerebral cortex isolated from pDECAP-PQBP1 transgenic mice and littermate wild-type (WT) mice by western blot analyses. PQBP1 expression in the pDECAP-PQBP1 transgenic mice was 50% of that in WT mice (Fig. 1C) . There was no apparent change in the expression levels of GAPDH, a-Tubulin, b-Actin, GFAP and MAP2. In the nucleotide BLAST search at NCBI (http://blast.ncbi.nlm.nih.gov), no homologous gene sequence was found with the PQBP1 fragment from 295 to 792 bp.
PQBP1-KD mice have normal motor function
First, we assessed spontaneous activity and motor function in PQBP1-KD mice. Spontaneous activity monitored under 12 h light/dark cycle was not changed in PQBP1-KD mice at the age of 1.5, 3 and 6 months (Supplementary Material, Fig. S2A ). We also tested their motor function using the standard paradigm for the accelerating rotating rod (rotarod) apparatus, but found no differences between PQBP1-KD and WT mice in the rotarod test (Supplementary Material, Fig. S2B ).
PQBP1-KD mice showed abnormal anxiety-related behavior
PQBP1-KD mice behave almost normally in ordinary conditions. However, we noticed that they sometimes stayed in the center of cage. Therefore, we used three behavioral paradigms, the open-field test, the light -dark exploration test and the elevated plus maze test, to evaluate anxiety-related behavior in PQBP1-KD and WT mice. We performed these experiments at three different ages: 1.5 (the earliest time point for behavior analysis due to the technical and ethical regulations), 3 and 6 months.
First, total locomotion activity and anxiety-like responses of PQBP1-KD and WT mice were measured in a novel open field. In comparison to WT mice, KD mice spent a significantly greater percentage of time in the center square where anxiety is triggered (P , 0.05) ( Fig. 2A) . No difference was observed in total locomotion activity between the genotypes ( Fig. 2A) . Anxiety-related behavior was also tested in the light -dark exploration test as described previously (20) . In the lightdark exploration test, PQBP1-KD mice spent more time in light box when compared with WT mice (P , 0.01) (Fig. 2B) . Although the total locomotion distance in the light and dark box did not differ between genotypes, PQBP1-KD mice traveled significantly farther in the light box (P , 0.05) (Fig. 2B) . The first latency to enter the dark box and the number of transitions between the light and dark boxes did not differ between the genotypes (data not shown). These abnormal behaviors in the open-field and light -dark exploration tests were detected at 1.5 months and resisted at least to 6 months ( Fig. 2A and B) , suggesting that these phenotypes started in pups. Therefore, neurochemical abnormalities described later (Figs 4-8) might occur during development, whereas, in this study, we focus on the analysis of adult PQBP1-KD mice (1.5 -6 months). Developmental analysis of behavior of newborn pups will be reported elsewhere in the future.
PQBP1-KD mice showed abnormal anxiety-related cognition
We next performed the repetitive elevated plus maze test to evaluate the anxiety-related behavior and memory (21 -24) . The mice were placed on the same maze twice with a 3 h interval. In the first trial, PQBP1-KD mice stayed for a longer time on the open arms than littermate (WT) mice (Fig. 3A) . In the second trial, the difference became larger. WT mice hardly stayed on the open arms where the anxiety was induced, whereas PQBP1-KD mice stayed on the open arms for a half time of the first trial (Fig. 3A) . The difference was statistically significant (Student's or Welch's test, P , 0.01). In addition, PQBP1-KD mice were more active on the open arms than the WT mice (Fig. 3A1) . These results were similarly observed from 1.5 to 6 months (Fig. 3A1 ). In the repetitive elevated plus maze test, the improvement of 'time on open arm' from trial 1 to trial 2 was not significantly different between WT and PQBP1-KD mice, in contrast to the elongation of 'time on open arm' at trial 1 (Fig. 3A2) . It suggests that abnormal cognition rather than memory in PQBP1-KD mice was unraveled by the elevated plus maze test.
We also examined PQBP1-KD mice with novel object recognition test (Fig. 3B) , a non-aversive memory task that relies on the natural exploratory behavior of mice. In this task, mice were exposed to two identical objects for 10 min during the training session (trials 1 and 2). We then tested their cognition and memory by replacing one of the objects in trials 3 and 4 ( Fig. 3B1, 3B2 , upper scheme). PQBP1-KD mice spent more time for exploring in trial 2, suggesting that their exploration is not dependent on the novel object recognition (Fig. 3B1) . Since reduction of the exploratory time from trial 1 to trial 2 was significantly smaller in PQBP1-KD mice than in WT mice (Supplementary Material, Fig. S3 ), PQBP1-KD mice might not learn or remember the object in trial 1. In trials 3 and 4, the exploring time in Area B was increased from trial 2 in WT mice but not in PQBP1-KD mice (Fig. 3B2) , suggesting that KD mice did not distinguish novel and old objects. The ratio between trials 2 and 3 was significantly different (Fig. 3B ). The similar difference was observed between trials 2 and 4 ( Fig. 3B) .
Abnormal anxiety-related cognition of PQBP1-KD mice was observed in the repetitive elevated plus maze test (Fig. 3A) and the extent of changes was almost similar in trial 1 and trial 2. Meanwhile, in the novel object recognition test, exploring time to the old object of PQBP1-KD mice was elongated in trial 2, although it was normal in trial 1 (Fig. 3B1) . Moreover, the normal increase of exploring time from trials 2 to 3 or from trials 2 to 4 was not found in PQBP1-KD mice (Fig. 3B2 ). For this increase of exploring time, WT mice remembered the old object in trial 1/2 and compared it with a new one in trial 3/4. Therefore, PQBP1 hypofunction might also impair a kind of memory related to anxiety.
We evaluated PQBP1-KD mice with the fear-conditioning test, in which mice were conditioned to a foot shock context and an auditory cue (the conditioned stimulus) and tested 24 h later. There were no significant differences in the fearconditioning test between the genotypes, although PQBP1-KD mice had a tendency to present less freezing responses compared with WT mice in the contextual test and cued test (Fig. 3C) .
In Morris water maze test, PQBP1-KD mice did not show significant reduction of the ordinary spatial memory (Supplementary Material, Fig. S4 ), although PQBP1-KD mice tended to show lower values than WT mice.
Neurons of PQBP1-KD mice show reduction of c-fos and hypoacetylation of histone H3
We next intended to analyze the molecular mechanisms underlying the behavioral and cognitive abnormalities in PQBP1-KD mice. First, we examined expression of c-fos an immediate early gene that has been used as a marker of neuronal activity in anxiety-related behavior and memory (25 -27) . At 1.5, 3 and 6 months of age, brain samples prepared before and 2 h after behavior tests (Fig. 4) . We focused on amygdala, prefrontal cortex and hippocampus, because these regions play critical roles in cognition and emotional memory (reviewed in 28). Western blot analysis revealed a clear upregulation of c-fos protein in response to the behavior tests (repetitive elevated plus maze test) in WT mice (age-matched littermates) but not in PQBP1-KD mice (Fig. 4A) . A significant reduction of c-fos after behavior tests was observed in all the tested brain regions of PQBP1-KD mice (Fig. 4B ). In addition, the levels of c-fos were similarly reduced at all time points from 1.5 to 6 months (Fig. 4B) . Consistently, immunohistochemistry of PQBP1-KD mice revealed significant reduction of c-fos protein in these brain areas after behavior tests (Fig. 4C) . Co-staining with neuronal marker NeuN confirmed c-fos reduction occurred in neurons ( Fig. 4D and E) . We employed another marker of the memory-related transcriptional upregulation, acetylated histone H3, which has been suggested to reflect anxiety-related behavior and memory (29) (30) (31) (32) (33) . We compared the signal intensities of acetylated H3 between PQBP1-KD and age-matched littermate (WT) mice in western blot analyses and immunohistochemistry (Fig. 5) . In this case, acetylated H3 was not significantly upregulated by behavior tests in WT mice (Fig. 5A) . However, the levels of acetylated H3 were lower in PQBP1-KD mice both before and after behavior tests (Fig. 5A ). The levels of acetylated H3 were similarly reduced at all time points from 1.5 to 6 months in cortex, hippocampus and amygdala when compared with those in WT mice (P , 0.05) (Fig. 5B, Supplementary Material, Fig. S5 ). Immunohistochemistry performed at 3 -6 months of age also supported the decrease of acetylated H3 in prefrontal cortex, hippocampus and amygdala (Fig. 5C ). Quantitative analyses of the immunostain signals of acetylated histone H3 in NeuNpositive neurons (Fig. 5D ) confirmed that acetylated H3 were reduced in neurons of these brain regions (Fig. 5E ).
PBA rescues impairment of anxiety-related cognition in PQBP1-KD mice
Finally, we tested whether transcriptional up-regulation can rescue the phenotype of PQBP1-KD mice at 7 months of age (Figs 6 and 7). We employed a HDAC inhibitor, PBA, which is known to increase acetylation of histone H3 and H4 in the mouse brain (34) . PQBP1-KD and aged-matched littermate (WT) mice received daily intra-peritoneal injections of PBA or vehicle (phosphate buffered saline, PBS) for 4 weeks from the age of 7 months (Fig. 6A ). As expected, administration of PBA for 4 weeks increased the level of acetylated H3 both in the PQBP1-KD and WT mouse brains (Fig. 6B ). The level of acetylated H3 in PBA-treated KD-mice was normalized to that of WT mice without PBA treatment (Fig. 6B ). The similar recovery was observed in immunohistochemistry ( Fig. 6C) . Interestingly, PBA-treated WT mice showed a higher level of acetylated H3 than the ordinary level of the PBA-non-treated WT mice ( Fig. 6B and C). Ã P , 0.05 in Student's t-test or Welch's t-test. (B1) The novel object recognition test was performed according to the scheme. Trials 1 and 2 were for memory consolidation, and trials 3 and 4 were for recognition of novel objects (upper scheme). Total exploratory time in each trial is shown at three different ages. No significant difference was observed between genotypes in trial 1, whereas total exploratory time in trial 2 was significantly longer in PQBP1-KD mice at 3 and 6 months.
Ã P , 0.05 in Student's t-test or Welch's t-test. (B2) Percentage exploring to a new object (B/AþB) is shown. Trials 1 and 2 are for learning of old objects. The increase of exploring to a new object from trial 2 to trail 3 or from trial 2 to trial 4 was observed in WT mice but not in PQBP1-KD mice. In trial 3, the relative exploring to a new object was lower in PQBP1-KD mice. The ratios of trial 2 or 3 to trial 1 were also abnormal in multiple aspects. Upregulation of c-fos in response to learning task was impaired in PQBP1-KD mice. (A) Expression levels of c-fos protein before and after behavior tests were examined by western blot analyses in PQBP1-KD and WT (age-matched littermates) mice at the age of 1.5, 3 and 6 months. Quantitative analysis of c-fos band intensities (standardized by GAPDH) is shown below. Mean þ SD. Statistical analysis was performed with F-test followed by Student's t-test:
Ã P , 0.01. (B) Western blot analyses were performed 2 h after behavior tests with protein extracts from cortex, hippocampus and amygdala using anti-c-fos and anti-GAPDH antibodies at the age of 1.5, 3 and 6 months (upper panels). Quantitative analysis of western blots is shown below (lower panels). Expression level of c-fos protein is expressed as a ratio to GAPDH (lower). Data are presented as mean þ SD of the results from four animals. Statistical analyses by Student's t-test: . Acetylation of H3 was impaired in PQBP1-KD mice. (A) Expression levels of acetylated histone H3 protein (Ac-Lys14) before and after behavior tests were examined by western blot analyses in PQBP1-KD and WT (age-matched littermates) mice. Student's t-test indicated significant differences.
Ã P , 0.05. (B) Western blot analysis performed 2 h after behavior tests with protein extracts from cortex, hippocampus and amygdala using anti-acetylated H3 (AcH3) and anti-H3 antibodies (upper) at the age of 1.5, 3 and 6 months. Quantification of western blot analyses using anti-acetylated H3 (AcH3) and anti-H3 antibodies revealed that acetylated/total H3 ratio was reduced in PQBP1-KD mice (lower). Data are presented as mean þ SD of the results from four mice of each group. Statistical analyses by Student's t-test or Welch's t-test: The recovery by PBA was tested also with behavior tests. In the novel open-field test, PBA-treated PQBP1-KD mice spent less time in the center square than PBS-treated PQBP1-KD mice (Fig. 7A) , indicating that PBA improved the anxiety-reduced behavior. In the light -dark exploration test, PBA-treated PQBP1-KD mice spent less time in light box when compared with PBS-treated PQBP1-KD mice (P , 0.01) (Fig. 7B) , indicating the similar improvement of anxiety deficiency. These results indicate that HDAC inhibitor (PBA) improved the abnormal anxiety-related behaviors of PQBP1-KD mice. Despite of the super normal level of acetylated H3 (Fig. 6B -D) , the anxiety-related behavior was not altered in PBA-injected WT mice ( Fig. 7A and B) , suggesting that the transcriptional basis for behavior was saturated.
We further performed the repetitive elevated plus maze to test the effect of PBA. When compared with PBS-treated PQBP1-KD mice, PBA-treated PQBP1-KD mice spent less time in the open arms (P , 0.01) (Fig. 7C) . In this case, not only the time at trial 1 but also the time reduction from trial 1 to 2 was also improved (Fig. 7C) . Thus, chronic injection of PBA recovered anxiety-related cognition in PQBP1-KD mice.
Finally, we confirmed that the HDAC inhibitor also rescued the response of c-fos protein to the behavior test (repetitive elevated plus maze test) in PQBP1-KD mice (Fig. 7D) .
Expression of other anxiety-related genes in PQBP1-KD mice Furthermore, we examined the possibility that expression changes of other genes underlie the abnormal anxiety-related cognition in PQBP1-KD mice. Serotonin pathway has been implicated in anxiety-related behavior. Thus, we decided to analyze expression of serotonin transporter and HT receptor 1A. Cyclic AMP-responsive element binding protein (CREB) was another candidate, because it is implicated in fear-related (or amygdala-related) memory formation (35) . Because PQBP1-KD showed abnormal cognition (Fig. 3A) and because we observed reduction of NMDA receptor subunit 1 (NR1) (but not NR2) in the olfactory memory system of Drosophila (unpublished data), we also included NR1 as a candidate. Since NF-kB is implicated in anxiety-related behavior (36) and is known to regulate NR1 gene expression (37), we added it to the candidates. Among these candidates: serotonin transporter, HT receptor 1A, NMDA receptor NR1 subunit, NF-kB p50 and CREB, western blot analyses showed reduction of NF-kB and NR1 in the cortex, hippocampus and amygdala of PQBP1-KD mice (Fig. 8A) . The reduced level was not significantly different before and after behavior tests. Serotonin transporter, HT receptor 1A and CREB did not show such reduction (Supplementary Material, Fig. S6 ). PBA partially recovered expression of NR1 and NF-kB in PQBP1-KD mice near to the levels of non-treated control mice (Fig. 8B) .
DISCUSSION
PQBP1 hypofunction induces abnormal anxiety-related cognition
Mutations identified so far in human PQBP1-linked MR patients lead to total or partial deletion of the C-terminal domain of the PQBP1 protein (5 -7). In addition, presumably due to the RNA decay of the truncated mRNA, the level of PQBP1 seems to be reduced substantially (5) . Therefore, hypofunction of PQBP1 is strongly suggested to cause MR symptoms. In this study, we reported the first hypomorph mouse model of PQBP1 and its impairment of anxiety-related cognition.
Downstream genes for abnormal anxiety-related cognition in PQBP1-KD mice
Analyses on molecular functions of PQBP1 have suggested its role in the connection between transcription and splicing (11 -15) . PQBP1 interacts with phosphorylation sites of the C-terminal domain of RNA Pol II (Pol II-CTD) (11) and with several proteins such as NpwBP and U5-15kD involved in RNA splicing (11, 14, 15) . Because phosphorylation of the second serine in a repeat sequence of Pol II-CTD enhances interaction of PQBP1 to Pol II, PQBP1 is considered to be a bridging molecule between transcription and splicing that functions during RNA elongation (11). Our previous results indicated that mutant Atx1 interacts with PQBP1/Pol II complex, disturbs the transcription-mRNA processing link and induces cell dysfunction by down-regulation of the active form of Pol II (11) . The accumulated line of evidence suggests that changes of certain anxiety-related behavior genes might underlie the less anxious behavior and the abnormal cognition in PQBP1-KD mice. As such downstream gene candidates, we found changes of expression in c-fos, NR1 and NF-kB (Figs 4 and 8 ).
An immediate early gene, c-fos has been used as a marker of neuronal activity in the analyses of anxiety-related behavior and memory (25 -27) . Also in PQBP1-KD mice, response of c-fos to behavior tests was impaired in neurons of amygdala, prefrontal cortex and hippocampus. As c-fos regulates multiple genes participating in synapse and spine formation (38) , the result suggests that reduction of c-fos impairs plasticity of neurons involved in anxiety-related behavior and cognition of PQBP1-KD mice.
Serotonin pathway has been implicated in anxiety-related behavior (39) . In addition, co-activation of c-fos and serotonin by stress in neurons of dorsal raphe nucleus (25) suggests that a downstream target molecule of c-fos could be serotonin. Thus, we tested expression of serotonin transporter and HT receptor 1A in PQBP1-KD and their response to PBA treatment. However, the result showed that both of the serotoninrelated genes were not changed in PQBP1-KD mice (Supplementary Material, Fig. S6 ) and that these genes did not respond to PBA (data not shown). We also tested expression of CREB which is implicated in fear-related (or amygdala-related) memory formation (35) . The basal level of CREB was not significantly changed in PQBP1-KD mice (Supplementary Material, Fig. S6 ) and it did not respond to PBA (data not shown), suggesting that CREB would not be a major factor in the pathway.
Because PQBP1-KD showed abnormal cognition (Fig. 3A) and because we observed reduction of NR1 (but not NR2) in the olfactory memory system of Drosophila (unpublished data), we tested the expression of NR1 as a candidate molecule in the downstream of c-fos and histone H3 acetylation. The result showed repression of NR1 in PQBP1-KD mice and its recovery by PBA (Fig. 8) in consistence with the results of behavior tests. As an AP1 site for c-fos binding exists in the upstream of mouse and human NR1 genes (http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book= frnrec&part=ch5#ch5.r45), c-fos might upregulate NR1 after behavior tests. Since NR1 expression was reported to be normal in conditional knockout mice of c-fos (40), c-fos seems to regulate only inducible but not basal gene expression of NR1. Meanwhile, hypoacetylation of histone H3 might cause the initial reduction of NR1 before the behavior tests.
On the other hand, histone H3 hypoacetlylation could induce reduction of NR1 in collaboration with other transcription factors like NF-kB that is known to regulate NR1 gene expression (37) . Consistently, we observed mild reduction of NF-kB p50 subunit in PQBP1-KD mice (Fig. 8A) . The NF-kB p50 subunit KO mice showed reduced anxiety-related behavior (41) similar to PQBP1-KD mice. NMDA receptor is a heterodimer composed of NR1 and NR2. Although the direct relationship between NR1 and anxiety has not been reported so far, NR2A KO mice exhibited decreased anxiety-related behavior (42) . These notions seem to support our hypothesis.
Connection from PQBP1-KD to anxiety-related genes
Furthermore, we found reduced acetylation of histone H3 in neurons of PQBP1-KD mice (Fig. 5 ) that might connect from PQBP1-KD to the reduced expression of anxiety-related genes. Interestingly, histone acetylation was reported to link to memory formation (30, 32, 43) . Histone complex interacts with DNA to regulate the higher structure of chromatin and control the accessibility of DNA for gene transcription. Generally, acetylation of histone H3 releases genomic DNA from histone complex to make it accessible for transcription factors and RNA polymerases, thereby upregulating gene transcription (44 -46) . Our results in study demonstrated that acetylation of histone H3 in PQBP1-KD mice were reduced in cortex, hippocampus and amygdala. Therefore, it is possible to imagine that the reduced acetylation of histone H3 would mediate the PQBP1's effect to target genes in the brain regions critical for anxiety-related cognition.
The pathway by which PQBP1-KD leads to histone H3 deacetylation has not been identified. However, transcription, RNA splicing and histone modification are closely linked. Multiple factors that mediate elongation, splicing and other RNA modification interact with Pol II-CTD in a phosphorylation-dependent manner (47,48). As described above, PQBP1 is such a molecule connecting splicing and transcription, and its functional disturbance leads to transcriptional repression (11) . In the transcriptional cessation under non-homologous end-joining of DNA double-strand breaks, Sin3p/Rpd3p histone deacetylase complex induces histone deacetylation around the break point for DNA repair (49) . We observed that RNA Pol II inhibition by alpha-amanitin induces DNA damage response (unpublished data), and it was reported that histone deacetylase is activated in DNA damage response (50) . Regarding the relationship between histone and splicing, H3 methylation is known to facilitate pre-mRNA splicing (51) , and inhibition of HAT leads to the block of splicing at A-like spliceosome (52) . Considering with these links among histone, RNA Pol II and spliceosome, abnormal transcription and splicing by PQBP1-KD might induce histone deacetylation.
Collectively, these data and considerations might be able to provide a hypothetical scheme that PQBP1-KD impairs expression of downstream genes involved anxiety-related behavior via histone H3 acetylation. However, further analyses using different types of animal models and human pathology and extensive investigation on the other signaling pathways are needed for complete understanding of the gene pathway that links molecular abnormality to patient symptoms.
PBA as a candidate for human therapy
This study also showed that HDAC inhibitor, PBA improved abnormal anxiety-related behavior and cognition in PQBP1-KD mice. The rescue effect strongly supported our hypothesis that regulation of certain genes via transcription or splicing might underlie the abnormal behavioral phenotypes in PQBP1-KD mice. An intriguing point obtained in this study was that we could improve such abnormalities in adult mice. Although the results were at the mouse level, the successful intervention for adult mice is encouraging for treatment of human MR patients. It might suggest that PQBP1-linked MR patients might be reversible even in adulthood. The use of HDAC inhibitor should be seriously considered for a group of MR related to gene expression regulation because a similar approach was successful also in Rubinstein -Taybi syndrome (29) .
It might be possible to imagine that non-specific effect(s) of PBA benefit mouse and ameliorate the symptoms. PBA actually possesses multiple biological activities like ammonia scavenging in urea cycle dysfunction (53) and regulation of ubiquitin -proteosome or ER stress pathway (54, 55) . However, PQBP1 is not involved in these biological functions. HDAC inhibitors including PBA are also expected as anti-cancer drugs that inhibit cell proliferation and induce apoptosis (56) , whereas these effects would not benefit the cognitive function. Furthermore, PBA has adverse effects like dyspepsia and fatigue in human patients (57) , and the overdose of sodium butyrate, a homologous molecule, deteriorates the symptoms in a mouse model of neurodegeneration (58) . Collectively, non-specific beneficial effects by PBA are difficult to consider as the cause for the improvement of cognition and memory in our mouse model. Specific beneficial effects of various HDAC inhibitors were reported in mouse or Drosophila models of polyQ diseases (58 -63), Parkinson's disease (64), amyotrophic lateral sclerosis (65) and Alzheimer's disease (AD) (66) . Among them, PBA was reported to mitigate the phenotype of HD mouse model via transcriptional improvement (61) . Related HDAC inhibitors, sodium butyrate and suberoylanilide hydroxamic acid also improve phenotypes of HD and DRPLA model mice through HDAC inhibition and transcriptional improvement (58, 62) . Interestingly, improved cognition was reported in the AD mouse model with nicotinamide that inhibits a Class III HDAC Sir2 deacetylase (67, 68) .
PBA has been already used for human patients of hyperammonemic encephalopathy due to ornithine transcarbamylase deficiency (53) or of inherited epilepsy due to glycosylphosphatidylinositol deficiency (69) . Furthermore, clinical trials of PBA have been performed in various cancers and neurodegenerative diseases (http://clinicaltrials.gov/ct2/ results?term=phenylbutyrate). A small part of patients showed dyspepsia and fatigue while no major side effect was reported. As the safety of PBA has been established in these clinical use and trials, it would be a good candidate for PQBP1-linked MR and its relevant developmental disorders.
PQBP1 in MR and neurodegneration
PQBP1 was isolated originally as a binding protein to the polyQ tract sequence (10) . PQBP1 is implicated in neurodegenerative pathologies because it interacts with mutant Atx1, the causative gene product of SCA1, and with Htt, the causative gene product of HD. The interaction with mutant polyQ proteins links to dysfunction of PQBP1 in transcription coupled with splicing (11) . We have shown in this study that a homologous dysfunction in transcription/splicing may occur in MR. However, a critical difference between MR and neurodegeneration is the onset of dysfunction. PQBP1 hypofunction would start from an embryonic stage in the MR pathology, whereas mutant polyQ proteins would disturb the PQBP1 function more strongly after the toxic (interacting) form accumulates by overwhelming the cell protection mechanisms such as ubiquitin -proteasome and authophagy systems. The chronological difference may be important for differentiating the critical period for therapeutic intervention of each symptom of MR or neurodegeneration.
MATERIALS AND METHODS
Construction of PQBP1 double-strand RNA expression vector
The plasmid to express PQBP1 double-strand RNA (pDECAP-PQBP1) was constructed by subcloning the last 498 bp (295-792 fragment) of the mouse PQBP1 coding region into the pDECAP vector as an inverted repeat with a 12 bp spacer (ATCTGCGGTACC). The primers, forward: CCGGAATTCTCAGTCCTGCTGTTTGGTTC and reverse: GCTCTAGAGGTACCGCAGATGCTGAGGACAAGT, were used to amplify anti-sense sequence with spacer, and the primers, forward: CGGGGTACCGCTGAGGACAAGTCGG AC and reverse: GCTCTAGATCAGTCCTGCTGTTTGGTTC, were used for amplifying sense sequence. The pDECAP vector contains cytomegalovirus promoter, ribozyme cassette and MAZ site for RNA Pol II pausing (70, 71) . There is no poly(A) addition signal in the construct.
Generation of pDECAP-PQBP1 transgenic mice
The 2.15 kb BglII -BamHI fragment of pDECAP-PQBP1 was freed from background sequences, purified and injected into fertilized mouse oocytes. The fertilized mouse oocytes were derived from matings between C57BL/6 mice. For genotyping, genomic DNA was prepared from tail biopsy and used for PCR. Integration of the DNA fragment was confirmed by PCR using three primer pairs: forward-1, 5
0 -GATCTTCAAT ATTGGCCATTAGC-3 0 , with reverse-1, 5 0 -ACGTAGATGT ACTGCCAAGTAG-3 0 , forward-2, 5 0 -TGCGGTAGTTTAT CACAGTT-3 0 , with reverse-2, 5 0 -GCTCTAGAGGTACCG CAGATGCTGAGGACAAGT-3 0 and forward-3, 5 0 -CGGGG TACCGCTGAGGACAAGTCGGAC-3 0 , with reverse-3, 5 0 -C ACACCTCCCCCTGAACCT-3 0 (Fig. 1A) . Four transgenic founder mice (F0) were produced and bred twice with C57BL/6J mice to produce F2 hemizygous transgenic animals. The effective suppression of PQBP1 was obtained in two lines, which were chosen for further studies.
Tissue preparation and western blotting
Two hours after the last behavior test, mice were deeply anesthetized and sacrificed by cervical dislocation, and brains were removed. For western blot sampling, brain tissues of PQBP1-KD mice (pDECAP-PQBP1 transgenic mice) and littermate WT mice dissolved in lysis buffer containing 62.5 mM Tris/HCl, pH 6.8, 2% (w/v) SDS, 2.5% (v/v) 2-mercaptoethanol and 5% (v/v) glycerol. Protein concentration was quantified by using the BCA method (Micro BCA Protein Assay Reagent Kit; Pierce Chemical, Rockford, IL, USA). These samples were separated by SDS -PAGE, transferred onto polyvinilydene difluoride membrane Fine Traps (Nihon Eido, Tokyo, Japan) through a semidry method, blocked by 5% milk in TBS with Tween-20 (TBST) (10 mM Tris/Cl, pH 8.0, 150 mM NaCl, 0.05% Tween-20) and incubated with appropriate antibodies as described below. The filters were incubated with each primary antibody for over night at 48C, with the corresponding horseradish peroxidase-conjugated second antibody for 1 h at room temperature in 5% milk/TBST. Finally, the target molecules were visualized through an enhanced chemiluminescence Western blotting detection system (Amersham Biosciences, GE Health Care Biosciences, Hong Kong). Immunoblotted bands were quantified using the Image J For quantitative comparison of western blot band intensities, we performed WB three times for each mouse. The means were averaged with the number of mice (indicated in figure or each figure legend) and SEM were calculated. After examining the variance among the groups, statistical analysis was performed by Student's t-test, Welch's t-test or one-way ANOVA, as described in the method of 'statistical analysis'.
Immunohistochemistry and histology
Mouse brains were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.4, embedded in paraffin and sectioned into 5 mm thick slices. Several sections were stained by hematoxylin-eosin for routine histology. For immunohistochemistry, the paraffin-embedded mouse sections were deparaffinized, rehydrated and then microwaved in 10 mM of citrate buffer, pH 6.0, for 15 min. These sections were incubated with primary antibodies for overnight at 48C, and finally with Alexa Fluor 488 and 594-labeled anti-IgGs (Invitrogen) for 1 h at room temperature. Primary antibodies of anti-NeuN (Millipore), anti-GFAP (NeoMarkers), anti-acetylated histone H3 (Upstate) and anti-c-Fos (Santa Cruz) were diluted at a ratio of 1:100.
Quantification of signal intensity
Signal intensity per cell was calculated by using MetaMorph software (Universal Imaging Corporation, Downingtown). After co-staining of anti-NeuN antibody with anti-c-Fos or anti-acetylated H3 antibody, NeuN-positive neurons were selected at random, and the fluorescence signal intensities per area (mm 2 ) of c-Fos or acetylated H3 were collected from at least three different slides of a mouse and more than 100 cells were measured in each slide. To exclude background fluorescence, we measured fluorescence of ten randomly selected non-cell existing tissue areas of each sample, and their mean value was subtracted from the cellular fluorescence signals on the same slide. The average of the signal intensities after background subtraction were calculated in each mouse, then the mean values from multiple mice (n ¼ 3 or 4) were statistically analyzed between the groups.
Conditions of testing animals
Mice were segregated by sex, housed two to five to a cage, provided with water and rodent chow and maintained on a 12 h light/dark cycle. All experiments were performed during the light phase (9:00 -18:00 h) using PQBP1-KD male mice and littermate WT male mice between 1.5 and 8 months of age and were conducted in accordance with the policies of the Institutional Animal Care and Use Committee of the Tokyo Medical and Dental University. 
Spontaneous activity
Spontaneous activity was measured in individually caged mice in their home cages under 12 h light/dark cycle. Their activity was monitored for 48 h using SCANET SV-10 (Toyo sangyo, Toyama, Japan).
Open-field test
Mice were placed in the center of an open-field space (50 cm Â 50 cm Â 40 cm [H]) and allowed to explore for 15 min. Light intensity was 70 lux in the center of the field. Distance traveled (cm) and % duration of staying at the center area of the field (30% of the field) were adopted as the indices.
Novel object recognition test
The novel object recognition test was started the day after the open-field test. During the training session, two novel objects were placed into the open field, and the spatial position of objects was counterbalanced between subjects. During the training session, mice were allowed to explore for 10 min on each of two consecutive days. The time spent exploring each object and total approach time was recorded. To test for memory retention, mice were placed back into the same box 3 and 24 h after a training session, in which one of the familiar objects used during the training session was replaced by a novel object and allowed to explore freely for 10 min. A preference index, a ratio of the amount of time spent exploring any one of the two objects (training session) or the novel object (retention session) over the total time spent exploring both objects was used to measure recognition memory.
Light -dark exploration test
Light box was made of white plastic (20 cm Â 20 cm Â 20 cm [H]) and illuminated by LEDs (250 lux at the center of the box); a CCD camera was equipped on the ceiling. Dark box was made of black plastic (20 cm Â 20 cm Â 20 cm [H]) and an infrared camera was equipped on the ceiling. There was a tunnel for transition on the center panel between the light box and dark box (3 cm Â 5 cm) with a sliding door. In the L -D box test, mice were individually introduced into the light box, and the door of the tunnel opened 3 s after the introduction of a mouse. Then mouse was allowed to move freely in the L -D box for 10 min. Total distance traveled, distance traveled in the light box, duration staying in the light box, numbers of the transition between light and dark box and the first latency to enter the dark box were measured as indices. 
Elevated plus maze test
Rotarod test
Mice were placed on a rotating rod (diameter: 3 cm), and the rotating speed was linearly increased from 3.5 r.p.m. to 35 r.p.m. in 300 s and continued at 35 r.p.m. until 360 s. Mice received nine trials (three trials per day for 3 consecutive days) with a 30-60 min rest interval between trials. The amount of time for each mouse to fall from the rod was recorded for each trial. The mean latency to fall off the rotarod was recorded and used in subsequent analysis.
Morris water maze test
The Morris water maze test was conducted in a circular pool of a 1 m diameter and filled with water at a temperature of 22.0 + 18C. Water was colored by white painting in order that mice could not see the platform (20 cm high, 10 cm diameter; 1 cm below the surface of water) or other cues under the water. There were some extra-maze landmark cues that were visible to the mice in the maze. Mice received six trials per day for 5 consecutive days. Each acquisition trial was initiated by placing an individual mouse into the water facing the outer edge of the maze at one of four designated starting point quasi-randomly, but the submerged platform remained constant for each mouse throughout testing. A trial was terminated when the mouse reached the platform, and the latency and distance swam were measured. Cut-off time of the trial was 60 s, and mice that did not reach the platform within 60 s were removed from the water and placed on the platform for 30 s before being toweled off and placed back into their home cage. The inter-trial interval was 6 min. After the 5 days' training, a probe test was conducted. In the probe test, the platform was taken away, and each mouse was placed into the water at the point of the opposite position of the target platform, and allowed to swim in the maze for 60 s. The distance swam, the number of crossings the position of the target platform and other three platforms, time staying in the quadrants of the four platforms were measured.
Contextual fear conditioning test
Contextual fear conditioning test was carried out the day after the Morris water maze test. This test consisted of three parts: a conditioning trial, a context test trial and a cued test trial. Fear conditioning was carried out on a clear plastic chamber equipped with a stainless steel grid floor (34 cm Â 26 cm Â 30 cm [H]). A CCD camera was equipped on the ceiling of the chamber and was connected to a video monitor and computer. The grid floor was wired to a shock generator. White noise (80 dB) was supplied from a loudspeaker as an auditory cue (the conditioned stimulus, CS). A continuous 0.4 mA foot shock (the unconditioned stimulus, US) for 2 s was administered at the end of the 30 s CS period. The conditioning trial consisted of a 2 min exploration period followed by two CS-US pairings separated by 1 min each. A context test was performed in the same conditioning chamber for 5 min in the absence of the white noise at 24 h after the conditioning trial. Further, a cued test was performed in an alternative context with distinct cues; the test chamber was different from the conditioning chamber in brightness, floor structure (no grid) and shape. The cued test was conducted 3 h after the contextual test and consisted of a 2 min exploration period (no CS) to evaluate the non-specific contextual fear followed by a 3 min CS period (no foot shock) to evaluate the acquired cued fear. Rate of freezing response of mice was measured as an index of fear memory.
Injection of PBA
PBA (Nacalai Tesque, Kyoto, Japan) was dissolved in PBS by titration with sodium hydroxide to pH 7.4. Mice received daily intraperitoneal injections of PBA solution (100 mg/kg/day, volume 5 ml/kg) or vehicle (PBS, 5 ml/kg), for 4 weeks from 7 months of age. The analyses were performed in the order of open-field test, light -dark exploration test and elevated plus maze test.
Statistical analysis
For statistical analysis of behavioral analyses, we first compared the variances among groups with F-test. When the variance was similar among groups, we used Student's t-test or one-way ANOVA. In the case that the variance was not similar, we used Welch's t-test. When a significant effect was found in one-way ANOVA, Bonferroni/Dunn post hoc comparisons were applied. Average and standard error of mean (SEM) were presented for each experimental parameter in one group.
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